Semaglutide

semaLyophilized powder

Semaglutide is a long-acting peptide that activates the GLP-1 receptor, one of the incretin hormone receptors. Prescription medicines containing it are FDA-approved for type 2 diabetes and chronic weight management; the research-grade vials listed here are a different, unapproved product. Below: today's vial sizes, prices through our link and the vendor's COA details.

Size

$3.85/mg · lot GS10-062026-1 · 99.91% · In stock

Price

$38.50

List

$55.00

Buy 10 mg at Nura Peptide

Price shown uses code thepeptidecatalog at Nura Peptide's checkout (30% off list).

Sold by Nura Peptide as GLP-1SG 10mg. The Peptide Catalog does not sell peptides; we earn a commission if you buy through this link, at no extra cost to you. For laboratory research use only, not for human or veterinary use. Not FDA-approved. Nothing on this page is medical or dosing advice.

Semaglutide research vial sold by Nura Peptide as GLP-1SG 10mg
Third-party tested≥99.91% reported purityResearch use only
Certificate of AnalysisLot GS10-062026-1 · 99.91%View
  • Certificate of Analysis published for every lot (Freedom Diagnostics Testing)
  • Current lots report 99.91% purity or higher
  • Ships from a U.S. fulfillment center, per Nura Peptide
  • Lyophilized powder · laboratory research use only
Research-context information only. Semaglutide is the active ingredient in FDA-approved products for type 2 diabetes and chronic weight management; research-peptide and compounded forms are not FDA-approved and are sold for research purposes only. Protocols, doses, and reactions reported below come from clinical trials and community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Vial sizes listed by the vendor

Semaglutide Vial Sizes, Prices & Lots

Semaglutide vial sizes, prices and lots at Nura Peptide
SizeListWith our codePer mgAvailabilityLot · purity
10 mg$55.00$38.50$3.85In stockGS10-062026-1 · 99.91%

Prices checked today, 6:20 AM CT on Nura Peptide's site, with code thepeptidecatalog applied. Lot data from Nura Peptide's COA page, checked today, 6:27 PM CT. Sizes not re-checked in the last 7 days are hidden. The vendor's checkout is final.

Verified test results

Semaglutide Certificate of Analysis

Nura Peptide publishes a third-party certificate for each lot of GLP-1SG 10mg. The figures below are copied from Nura Peptide's current-lot listings, checked today, 6:27 PM CT (refreshed hourly; hidden if older than 24 hours). Match the lot number on the vial to its certificate.

All lots on record: Nura Peptide COA library. How to check one: how to verify a peptide COA.

Semaglutide Dosing in Clinical Research

Weight Loss / Diabetes

Educational reference only. Individual responses vary. Consult healthcare provider before use.

Vial Size
3 mg
Reconstitution
2 ml BAC water
Dose
250 mcg (17 units on 1ml syringe)
Timing
AM
Frequency
Once per week
Duration
8 weeks on, 8 weeks off
Protocol Notes
Take same day each week on empty stomach. Titrate slowly to minimize GI side effects.

Why This Dosing Protocol

Why slow titration? GI side effects (nausea, diarrhea) are dose-dependent. Starting at 0.25mg and increasing every 4 weeks allows the body to adapt, dramatically reducing side effects compared to jumping to full dose.

Why weekly? The albumin-binding acyl chain extends half-life to ~7 days. One injection provides consistent appetite suppression all week — no daily dosing needed.

Why same day each week? Maintains consistent blood levels. Shifting days creates peaks and troughs that can worsen side effects.
Full Dosing GuideReconstitution CalculatorCycle Cost Calculator
Popular Stack Protocols1 stack

Commonly paired protocols from the peptide research community. Educational reference only.

Semaglutide + Tirzepatide

Weight Loss (Sequential)
Semaglutide
Dose
250 mcg weekly
Vial Size
3 mg
Reconstitution
2 ml BAC water
Tirzepatide
Dose
0.5 mg 3x/week
Vial Size
10 mg
Reconstitution
2 ml BAC water
Timing
AM
Frequency
Sequential — not taken simultaneously
Duration
Until goal weight, then maintenance
NOT a simultaneous stack — these are sequential options. Start with semaglutide (GLP-1 only), and if plateauing, transition to tirzepatide (dual GIP/GLP-1) for stronger effects. Some protocols alternate. Never combine both simultaneously due to overlapping GLP-1 receptor agonism and compounding GI side effects.

How Semaglutide Works: The GLP-1 Receptor

GLP-1 Receptor Agonist — Incretin Mimetic

Receptor → Metabolic Cascade → Weight & Glucose → Outcomes

1
Target

GLP-1 Receptors (Pancreas, Brain, Gut)

Semaglutide mimics the incretin hormone GLP-1, binding receptors in the pancreas (insulin release), brain (appetite suppression), and gut (gastric emptying). Unlike natural GLP-1 which lasts minutes, semaglutide's modifications extend its half-life to ~7 days.

2
Cellular Signal

cAMP/PKA → Insulin Secretion + Central Satiety

GLP-1 receptor activation triggers insulin release from pancreatic beta cells (only when blood sugar is elevated — reducing hypoglycemia risk). In the brain, it activates satiety centers that reduce hunger and food-seeking behavior. In the gut, it slows gastric emptying.

3
Systemic Effect

Reduced Appetite + Improved Glucose → Weight Loss

The combined effects — reduced hunger, slower digestion, improved insulin sensitivity — produce 15-20% body weight reduction in clinical trials. Cardiovascular benefits have also been demonstrated, with reduced risk of major cardiac events.

4
What You Notice

Appetite Reduction → Steady Weight Loss → Metabolic Health

Reduced hunger and food noise are typically noticed within the first week. Weight loss begins within 2-4 weeks and continues steadily. GI side effects (nausea) are common initially but improve with slow titration. Blood sugar improvements measurable within weeks.

What Makes This Peptide Different

Semaglutide is the most widely prescribed GLP-1 for weight lossIts 7-day half-life allows weekly dosing. Compared to Tirzepatide (dual agonist, more weight loss) and Liraglutide (daily dosing, less weight loss), semaglutide offers the best balance of efficacy, convenience, and established safety data.

Semaglutide Clinical Evidence

Two parallel grades per outcome — clinical RCT depth and real-world community adoption. See the Research Overview below for citations and detail.

OutcomeClinical EvidenceCommunity Evidence
Body weight reduction (obesity)StrongStrong
HbA1c reduction in T2DStrongStrong
Cardiovascular event reductionStrongStrong
MASH / liver fibrosisModerateModerate

Semaglutide Research Overview

Outcome-by-outcome look at what the evidence actually supports for Semaglutide, including human vs. animal study counts and our editorial take on each.

Body weight reduction in obesity

Clinical:StrongCommunity:Strong

STEP-1 (Wilding 2021, n=1961) randomized adults with overweight/obesity to once-weekly semaglutide 2.4 mg or placebo for 68 weeks and showed mean body weight reduction of 14.9% vs 2.4% placebo. The STEP program (1-8) replicated the effect across diabetic, adolescent, and post-bariatric populations. This is the largest weight-loss effect of any approved chronic weight-management agent prior to tirzepatide.

8 human studies · 6 animal studies

Key findings & citations
  • STEP-1: 14.9% mean weight loss vs 2.4% placebo at 68 weeks.
  • 50.5% of treated patients achieved ≥15% body weight reduction.
  • Effect maintained across multi-year follow-ups; weight regain on discontinuation is documented.

Our take

Until tirzepatide showed up, this was the standard. Still the most widely-prescribed chronic weight-management agent globally.

Cardiovascular outcomes

Clinical:StrongCommunity:Strong

Lincoff 2023 (SELECT, n=17604) showed semaglutide reduced major adverse cardiovascular events by 20% (HR 0.80) in adults with established cardiovascular disease and overweight/obesity *without diabetes*. SUSTAIN-6 (Marso 2016) previously showed CV benefit in T2D. This is the first weight-loss agent with a hard CV outcome benefit in non-diabetic populations.

2 human studies · 4 animal studies

Key findings & citations
  • SELECT: 20% reduction in MACE (HR 0.80, p<0.001) over 40 months in non-diabetic CVD patients.
  • SUSTAIN-6: 26% reduction in MACE in T2D + CVD (HR 0.74).
  • 16.6% discontinuation in semaglutide arm vs 8.2% placebo — GI tolerance is the limiter.

Our take

The first chronic weight-management drug to show cardiovascular benefit independent of glycemic control. Hard outcome data, not surrogate.

MASH / fibrosis

Clinical:ModerateCommunity:Moderate

Newsome 2021 (NEJM, n=320) showed 0.4 mg daily semaglutide produced NASH resolution without fibrosis worsening in 59% of patients vs 17% placebo at 72 weeks. The Phase 3 ESSENCE trial (2025) confirmed the histology benefit but fibrosis improvement remains harder to demonstrate.

1 human study · 4 animal studies

Key findings & citations
  • Newsome 2021: 59% NASH resolution at 0.4 mg vs 17% placebo (p<0.001).
  • Fibrosis stage improvement was not statistically significant in Phase 2.
  • ESSENCE Phase 3 (Sanyal 2025) confirmed MASH histology benefit at 72 weeks.

Our take

Real signal on inflammatory MASH; fibrosis benefit is less clean. Reasonable adjunct in MASH but not a fibrosis-reversal agent.

What Semaglutide doesn't do

Claims that current evidence does not support. Worth knowing before you set expectations.

Technical specifications

Semaglutide chemical & analytical data

Also known as
sema
Sold by Nura Peptide as
GLP-1SG 10mg
Receptor targets
GLP-1R
Backbone length
31 amino acids
Modifications
Aib at position 8; C18 fatty acid acylation at Lys26; Arg substitution at position 34
Half-life (clinical PK)
~7 days (weekly dosing)
Form
Lyophilized (freeze-dried) powder in a sealed vial
Presentation
10 mg
Purity on current lots (COA)
99.91%
Testing laboratory
Freedom Diagnostics Testing
Regulatory status
Active ingredient in FDA-approved prescription products; research-grade vials are not FDA-approved.

Semaglutide Reconstitution Calculator

Dilution math and unit conversions. Prefilled using a common vial size for this peptide.

Open calculator

Storage & Handling

Storage at a glance

Proper storage temperatures, shelf life, reconstitution best practices, and travel tips for lyophilized and reconstituted peptides.

Powder: Freezer
1+ year at -20°C
Reconstituted: Fridge
4 weeks max at 2-8°C
View Complete Storage Guide

Handling specifics

Educational overview on storage, labeling, and traceability considerations for lab environments. Consult primary literature and vendor documentation for specifics.

Powder storage (very stable)
  • Freezer (-20°C): 1+ year
  • Refrigerator (2-8°C): 1-3 months
  • Room temperature: 2-3 weeks (emergency only)
Reconstituted storage (fragile)
  • MUST refrigerate at 2-8°C
  • 4-week maximum shelf life
  • NEVER freeze after reconstitution
  • Use bacteriostatic water for multi-dose

11 answers

Semaglutide FAQ: Buying, COA, Storage & Research

How does semaglutide work for weight loss?
Semaglutide mimics GLP-1, a hormone that reduces appetite by acting on brain receptors, slows stomach emptying to increase fullness, and improves insulin sensitivity. This combination leads to reduced calorie intake and significant weight loss — averaging 15-20% of body weight in clinical trials.
Are there different semaglutide formulations?
Yes, semaglutide is available in formulations for type 2 diabetes (lower doses) and weight management (higher doses up to 2.4mg weekly). The active ingredient and mechanism are identical; the difference is approved indication and dosing.
What are the common side effects?
Most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These typically improve over the first few weeks as your body adjusts. Starting at a low dose and gradually increasing helps minimize these effects. Serious but rare side effects include pancreatitis and gallbladder problems.
How long do I need to take semaglutide?
Semaglutide is typically used long-term for weight maintenance. Studies show that weight regain often occurs after discontinuation. Many patients continue indefinitely, though some transition to lower maintenance doses. Discuss your long-term plan with your healthcare provider.
What is the typical semaglutide dosing schedule?
A common research dosage is 250 mcg (17 units on 1ml syringe) injected once per week in the AM on the same day each week. Protocol: 8 weeks on, 8 weeks off. Best taken on an empty stomach. Titrate slowly to minimize GI side effects.
How much weight can I expect to lose on semaglutide?
Clinical trials showed average weight loss of 15-17% of body weight over 68 weeks at the 2.4mg dose. Some patients lose more, some less — results vary based on diet, exercise, and individual response. About one-third of participants lost over 20% of their body weight.
Is semaglutide FDA approved?
Yes, semaglutide is FDA-approved under multiple brand names: for type 2 diabetes and for chronic weight management. An oral version is also approved for diabetes. This makes it one of the most studied and validated weight loss treatments available.
Can semaglutide be used with other weight loss methods?
Yes, semaglutide works best when combined with lifestyle changes including reduced calorie intake and increased physical activity. Clinical trials included lifestyle counseling. Some providers combine it with other approaches, though combining with other GLP-1 drugs is not recommended.
How long does reconstituted peptide last?
Once mixed with bacteriostatic water, peptides remain stable for up to 4 weeks when refrigerated at 2-8°C (36-46°F). Unopened powder can last 1+ year in the freezer. Get our complete Storage & Travel Guide.
Is this peptide legal to purchase?
Peptides sold "for research purposes only" are legal to purchase in the US, but are not FDA-approved for human use outside of specific medical applications. Always consult a healthcare provider before use.
New to peptides?
Take our Peptide Match tool to find the best peptide for your goals. You can also read our Complete Guide to Peptides to learn the basics.

Semaglutide Studies & Sources

The following peer-reviewed studies and official resources provide additional scientific context for this peptide:

Semaglutide Research Articles

guides

Semaglutide Dosage Chart: 250mcg/Week Protocol

Research peptide doses differ dramatically from FDA protocols. Covers 125-500mcg weekly, slow titration, and GI side effect management.

articles

Best Peptides for Liver Health

In trials, semaglutide resolved MASH in 63% of patients — but where do BPC-157 and glutathione really stand? Every liver peptide, evidence-graded.

comparisons

Retatrutide vs Semaglutide: Triple vs Single Agonist

Phase 2 trials reported 24.2% weight loss for retatrutide vs 14.9% for semaglutide in STEP 1 — but only one is FDA-approved. Full side-by-side.

comparison

Cagri+Tirz vs Cagri+Sema: Amylin Pairing Choice

REDEFINE 1 hit 22.7% with cagrilintide + semaglutide. Cagrilintide + tirzepatide has stronger GIP. Mechanistic case, trial data, and the open question.

Compare Semaglutide to alternatives

Side-by-side mechanism, dose, half-life, and vendor pricing.

Open compare →

Compare Semaglutide Vendors Before You Buy

Disclosure: we may earn affiliate commission from qualifying purchases. Educational information only — not medical advice.